taVNS for Pupillary Response
Trial Summary
What is the purpose of this trial?
This study has two parts. The study team will evaluate transcutaneous auricular vagal nerve stimulation (taVNS) and two sham settings during a passive task while measuring pupillary response. Second, the study team will assign either taVNS, sham, or no intervention during a go/no-go task and evaluate perceptual learning over three sessions which will also include measuring the pupillary response and electroencephalogram (EEG).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment taVNS for Pupillary Response?
Is transcutaneous auricular vagus nerve stimulation (taVNS) safe for humans?
Transcutaneous auricular vagus nerve stimulation (taVNS) is generally considered safe for humans, with only mild and temporary side effects like ear pain, headache, and tingling. A large review of studies found no serious adverse events linked to taVNS, making it a safe option for clinical use.23456
How is the treatment taVNS unique compared to other treatments for pupillary response?
taVNS is unique because it uses low-intensity electrical currents applied to the ear to stimulate the vagus nerve, which is different from other treatments that might not target this nerve or use electrical stimulation. This approach is being explored for its potential effects on pupil size, which is a novel area of research.12345
Research Team
Mario Svirsky, PhD
Principal Investigator
NYU Langone Health
Eligibility Criteria
This trial is for healthy individuals aged 18 to 65 with normal hearing. It's not suitable for those with heart muscle diseases, irregular heartbeats, implanted devices like pacemakers or vagal stimulators, metallic implants in their body, or pregnant women.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive transcutaneous auricular vagal nerve stimulation (taVNS) or sham during a passive task and a go/no-go task to evaluate perceptual learning and pupillary response over three sessions
Follow-up
Participants are monitored for changes in speed of learning and pupillary response after treatment
Treatment Details
Interventions
- Sham Stimulation
- Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)
Transcutaneous Auricular Vagal Nerve Stimulation (taVNS) is already approved in European Union, United States for the following indications:
- Epilepsy
- Depression
- Chronic Pain
- Anxiety
- Depression
- Anxiety
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor